Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

100 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
D-dimer testing to select patients with a first unprovoked venous thromboembolism who can stop anticoagulant therapy: a cohort study.
Kearon C, Spencer FA, O'Keeffe D, Parpia S, Schulman S, Baglin T, Stevens SM, Kaatz S, Bauer KA, Douketis JD, Lentz SR, Kessler CM, Moll S, Connors JM, Ginsberg JS, Spadafora L, Julian JA; D-dimer Optimal Duration Study Investigators. Kearon C, et al. Among authors: spadafora l. Ann Intern Med. 2015 Jan 6;162(1):27-34. doi: 10.7326/M14-1275. Ann Intern Med. 2015. PMID: 25560712 Clinical Trial.
Long-term risk of recurrence in patients with a first unprovoked venous thromboembolism managed according to d-dimer results; A cohort study.
Kearon C, Parpia S, Spencer FA, Schulman S, Stevens SM, Shah V, Bauer KA, Douketis JD, Lentz SR, Kessler CM, Connors JM, Ginsberg JS, Spadafora L, Julian JA. Kearon C, et al. Among authors: spadafora l. J Thromb Haemost. 2019 Jul;17(7):1144-1152. doi: 10.1111/jth.14458. Epub 2019 May 20. J Thromb Haemost. 2019. PMID: 31033194 Free article.
D-dimer levels and recurrence in patients with unprovoked VTE and a negative qualitative D-dimer test after treatment.
Kearon C, Parpia S, Spencer FA, Baglin T, Stevens SM, Bauer KA, Lentz SR, Kessler CM, Douketis JD, Moll S, Kaatz S, Schulman S, Connors JM, Ginsberg JS, Spadafora L, Liaw PC, Weitz JI, Julian JA. Kearon C, et al. Among authors: spadafora l. Thromb Res. 2016 Oct;146:119-125. doi: 10.1016/j.thromres.2016.06.023. Epub 2016 Jun 23. Thromb Res. 2016. PMID: 27354153
Antiphospholipid antibodies and recurrent thrombosis after a first unprovoked venous thromboembolism.
Kearon C, Parpia S, Spencer FA, Baglin T, Stevens SM, Bauer KA, Lentz SR, Kessler CM, Douketis JD, Moll S, Kaatz S, Schulman S, Connors JM, Ginsberg JS, Spadafora L, Bhagirath V, Liaw PC, Weitz JI, Julian JA. Kearon C, et al. Among authors: spadafora l. Blood. 2018 May 10;131(19):2151-2160. doi: 10.1182/blood-2017-09-805689. Epub 2018 Feb 28. Blood. 2018. PMID: 29490924 Free PMC article.
Pharmacomechanical Catheter-Directed Thrombolysis for Deep-Vein Thrombosis.
Vedantham S, Goldhaber SZ, Julian JA, Kahn SR, Jaff MR, Cohen DJ, Magnuson E, Razavi MK, Comerota AJ, Gornik HL, Murphy TP, Lewis L, Duncan JR, Nieters P, Derfler MC, Filion M, Gu CS, Kee S, Schneider J, Saad N, Blinder M, Moll S, Sacks D, Lin J, Rundback J, Garcia M, Razdan R, VanderWoude E, Marques V, Kearon C; ATTRACT Trial Investigators. Vedantham S, et al. N Engl J Med. 2017 Dec 7;377(23):2240-2252. doi: 10.1056/NEJMoa1615066. N Engl J Med. 2017. PMID: 29211671 Free PMC article. Clinical Trial.
DUCHESS: an evaluation of the ductal carcinoma in situ score for decisions on radiotherapy in patients with low/intermediate-risk DCIS.
Rakovitch E, Parpia S, Koch A, Grimard L, Soliman H, Stevens C, Perera F, Kong I, Senthelal S, Anthes M, Wiebe E, Cao J, Goldberg M, Smith S, Spadafora L, Whelan TJ. Rakovitch E, et al. Among authors: spadafora l. Breast Cancer Res Treat. 2021 Jul;188(1):133-139. doi: 10.1007/s10549-021-06187-7. Epub 2021 Apr 8. Breast Cancer Res Treat. 2021. PMID: 33830392
[Artificial intelligence in cardiology: the new HAL 9000?].
Bernardi M, Spadafora L, Dalla Vecchia LA, Pedretti RFE, Cenciarelli S, Zoccai GB, Versaci F. Bernardi M, et al. Among authors: spadafora l. G Ital Cardiol (Rome). 2026 Mar;27(3):159-167. doi: 10.1714/4650.46644. G Ital Cardiol (Rome). 2026. PMID: 41738417 Review. Italian.
Magnitude of blood pressure reduction in response to levosimendan infusion independently predicts in-hospital mortality in patients with acute heart failure.
Sarto G, Simeone B, Sbandi F, Valenti V, Forte M, Spadafora L, Bernardi M, Golino M, Tres G, Cantiello G, Frati L, Frati G, Di Mario R, Colaiori I, Biondi-Zoccai G, Versaci F, Sciarretta S. Sarto G, et al. Among authors: spadafora l. J Cardiovasc Pharmacol. 2026 Feb 23. doi: 10.1097/FJC.0000000000001811. Online ahead of print. J Cardiovasc Pharmacol. 2026. PMID: 41729537
Correction to: Pharmacological prevention in cardio-oncology: from bench-to-bedside.
Avagimyan AA, Pogosova N, Fogacci F, Urazova O, Djndoyan Z, Mirzoyan L, Avetisyan G, Bernardi M, Spadafora L, Shafie D, Perone F, Taheri M, Cicero A, Zoccai GB, Asteggiano R, Madonna R, De Caterina R, Sarrafzadegan N. Avagimyan AA, et al. Among authors: spadafora l. Heart Fail Rev. 2026 Jan 20;31(1):20. doi: 10.1007/s10741-025-10590-3. Heart Fail Rev. 2026. PMID: 41557159 No abstract available.
Missing Device Details in Coronary Stent Dislodgment Case.
Bernardi M, Spadafora L, Biondi-Zoccai G. Bernardi M, et al. Among authors: spadafora l. Catheter Cardiovasc Interv. 2026 Feb;107(3):752-753. doi: 10.1002/ccd.70407. Epub 2025 Dec 8. Catheter Cardiovasc Interv. 2026. PMID: 41362067 No abstract available.
100 results